Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 9/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.34 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | CLK3 | P49761 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28655702 | 0.83 | CLK1 (0.47) | DYRK1ADYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL28668352 | 0.82 | TTK (0.48) | DYRK1ACLK1CLK2PTK2TTK | |
| SCHEMBL21723695 | 0.80 | DYRK1A (0.38) | DYRK1ALRRK2ALKDYRK3CSNK1E | |
| SCHEMBL22264434 | 0.76 | DYRK1A (0.61) | DYRK1ALRRK2DYRK3CSNK1ECLK1 | |
| SCHEMBL22264415 | 0.75 | CLK1 (0.45) | DYRK1ADYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL21609948 | 0.73 | DYRK1A (0.52) | DYRK1ALRRK2DYRK3CSNK1ECLK1 | |
| SCHEMBL22159325 | 0.73 | DYRK1A (0.54) | DYRK1ALRRK2DYRK3CSNK1ECLK1 | |
| SCHEMBL28593022 | 0.72 | LRRK2 (0.54) | LRRK2 | |
| SCHEMBL21609958 | 0.72 | DYRK1A (0.61) | DYRK1ADYRK3CSNK1ECLK1CLK2 | |
| SCHEMBL21609957 | 0.71 | DYRK1A (0.67) | DYRK1ALRRK2DYRK3CSNK1ECLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239474-A1 | PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2020-07-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239474-A1 | PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE | LRRK2, WEE1, WEE2 | DYRK1A 897/4885LRRK2 1/4885ALK 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.